Biobanking Market (By Product: Equipment, Consumables, Laboratory Information Systems; By Service: Biobanking and Repository, Validation/Qualification, Lab Processing, Cold Chain, Logistic, Others; By Biospecimen Type: Human Tissues, Stem Cells, Organs, Others; By Biobank: Physical Biobanks, Virtual Biobanks; By Application; By Ownership; By Storage Type) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Biobanking Market, by Service, 2024-2033
7.1.1. Biobanking and Repository
7.1.1.1. Market Revenue and Forecast (2021-2033)
7.1.2. Validation/Qualification
7.1.2.1. Market Revenue and Forecast (2021-2033)
7.1.3. Lab Processing
7.1.3.1. Market Revenue and Forecast (2021-2033)
7.1.4. Cold Chain Logistic
7.1.4.1. Market Revenue and Forecast (2021-2033)
7.1.5. Other
7.1.5.1. Market Revenue and Forecast (2021-2033)
8.1. Biobanking Market, by Product, 2024-2033
8.1.1. Equipment
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Laboratory Information Systems
8.1.3.1. Market Revenue and Forecast (2021-2033)
9.1. Biobanking Market, by Biospecimen, 2024-2033
9.1.1. Human Tissues
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Stem Cells
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Organs
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
10.1. Biobanking Market, by Biobank, 2024-2033
10.1.1. Physical Biobanks
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Virtual Biobanks
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. Biobanking Market, by End-use, 2024-2033
11.1.1. Drug Discovery and Clinical Research
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Therapeutics
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Clinical Diagnostics
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2021-2033)
12.1. Biobanking Market, by Type of Biobank, 2024-2033
12.1.1. Population-based Biobanks
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Disease-oriented Biobanks
12.1.2.1. Market Revenue and Forecast (2021-2033)
13.1. Biobanking Market, by Ownership, 2024-2033
13.1.1. National/regional agency
13.1.1.1. Market Revenue and Forecast (2021-2033)
13.1.2. Non-Profit Organization
13.1.2.1. Market Revenue and Forecast (2021-2033)
13.1.3. Universities
13.1.3.1. Market Revenue and Forecast (2021-2033)
13.1.4. Private Organization
13.1.4.1. Market Revenue and Forecast (2021-2033)
14.1. North America
14.1.1. Market Revenue and Forecast, by Service (2021-2033)
14.1.2. Market Revenue and Forecast, by Product (2021-2033)
14.1.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.1.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.1.5. Market Revenue and Forecast, by End-use (2021-2033)
14.1.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.1.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Service (2021-2033)
14.1.8.2. Market Revenue and Forecast, by Product (2021-2033)
14.1.8.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.1.8.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.1.8.5. Market Revenue and Forecast, by End-use (2021-2033)
14.1.8.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.1.8.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Service (2021-2033)
14.1.9.2. Market Revenue and Forecast, by Product (2021-2033)
14.1.9.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.1.9.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.1.9.5. Market Revenue and Forecast, by End-use (2021-2033)
14.1.9.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.1.9.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Service (2021-2033)
14.2.2. Market Revenue and Forecast, by Product (2021-2033)
14.2.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.2.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.2.5. Market Revenue and Forecast, by End-use (2021-2033)
14.2.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.2.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Service (2021-2033)
14.2.8.2. Market Revenue and Forecast, by Product (2021-2033)
14.2.8.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.2.8.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.2.8.5. Market Revenue and Forecast, by End-use (2021-2033)
14.2.8.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.2.8.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Service (2021-2033)
14.2.9.2. Market Revenue and Forecast, by Product (2021-2033)
14.2.9.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.2.9.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.2.9.5. Market Revenue and Forecast, by End-use (2021-2033)
14.2.9.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.2.9.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Service (2021-2033)
14.2.10.2. Market Revenue and Forecast, by Product (2021-2033)
14.2.10.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.2.10.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.2.10.5. Market Revenue and Forecast, by End-use (2021-2033)
14.2.10.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.2.10.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Service (2021-2033)
14.2.11.2. Market Revenue and Forecast, by Product (2021-2033)
14.2.11.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.2.11.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.2.11.5. Market Revenue and Forecast, by End-use (2021-2033)
14.2.11.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.2.11.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Service (2021-2033)
14.3.2. Market Revenue and Forecast, by Product (2021-2033)
14.3.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.3.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.3.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.3.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Service (2021-2033)
14.3.8.2. Market Revenue and Forecast, by Product (2021-2033)
14.3.8.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.3.8.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.3.8.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.8.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.3.8.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Service (2021-2033)
14.3.9.2. Market Revenue and Forecast, by Product (2021-2033)
14.3.9.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.3.9.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.3.9.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.9.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.3.9.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Service (2021-2033)
14.3.10.2. Market Revenue and Forecast, by Product (2021-2033)
14.3.10.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.3.10.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.3.10.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.10.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.3.10.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Service (2021-2033)
14.3.11.2. Market Revenue and Forecast, by Product (2021-2033)
14.3.11.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.3.11.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.3.11.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.11.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.3.11.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Service (2021-2033)
14.4.2. Market Revenue and Forecast, by Product (2021-2033)
14.4.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.4.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.4.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.4.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Service (2021-2033)
14.4.8.2. Market Revenue and Forecast, by Product (2021-2033)
14.4.8.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.4.8.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.4.8.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.8.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.4.8.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Service (2021-2033)
14.4.9.2. Market Revenue and Forecast, by Product (2021-2033)
14.4.9.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.4.9.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.4.9.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.9.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.4.9.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Service (2021-2033)
14.4.10.2. Market Revenue and Forecast, by Product (2021-2033)
14.4.10.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.4.10.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.4.10.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.10.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.4.10.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Service (2021-2033)
14.4.11.2. Market Revenue and Forecast, by Product (2021-2033)
14.4.11.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.4.11.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.4.11.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.11.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.4.11.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Service (2021-2033)
14.5.2. Market Revenue and Forecast, by Product (2021-2033)
14.5.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.5.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.5.5. Market Revenue and Forecast, by End-use (2021-2033)
14.5.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.5.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Service (2021-2033)
14.5.8.2. Market Revenue and Forecast, by Product (2021-2033)
14.5.8.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.5.8.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.5.8.5. Market Revenue and Forecast, by End-use (2021-2033)
14.5.8.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.5.8.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Service (2021-2033)
14.5.9.2. Market Revenue and Forecast, by Product (2021-2033)
14.5.9.3. Market Revenue and Forecast, by Biospecimen (2021-2033)
14.5.9.4. Market Revenue and Forecast, by Biobank (2021-2033)
14.5.9.5. Market Revenue and Forecast, by End-use (2021-2033)
14.5.9.6. Market Revenue and Forecast, by Ownership (2021-2033)
14.5.9.7. Market Revenue and Forecast, by Type of Biobank (2021-2033)
15.1. Thermo Fisher Scientific Inc.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Tecan Trading AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. QIAGEN
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Hamilton Company
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Brooks Life Sciences
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. TTP Labtech
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. VWR International, LLC.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Promega Corporation
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Worthington Industries
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. BD
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
15.11. Merck KGaA
15.11.1. Company Overview
15.11.2. Product Offerings
15.11.3. Financial Performance
15.11.4. Recent Initiatives
15.12. Biokryo GmbH
15.12.1. Company Overview
15.12.2. Product Offerings
15.12.3. Financial Performance
15.12.4. Recent Initiatives
15.13. Cell&Co BioServices
15.13.1. Company Overview
15.13.2. Product Offerings
15.13.3. Financial Performance
15.13.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client